Risk factors for infection in haematology patients treated with rituximab
- 11 December 2008
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 82 (1) , 26-30
Abstract
Objectives: Although rituximab therapy is not considered to be closely associated with infection, there have been reports of serious infections in patients treated with rituximab. We performed a statistical retrospective analysis to clarify the risk factors for infection in patients receiving rituximab therapy.Methods: A retrospective study of data from clinical records was performed that targeted haematology patients treated at our university hospital between April 2003 and October 2006. We selected 63 patients with CD20‐positive lymphoma whose peripheral blood immunoglobulin levels had been measured within 6 months before and after rituximab therapy. Logistic regression analysis was used to investigate the risk factors for serious infection in these patients.Results: The three risk factors identified were: 1) reduction in IgM after administration of rituximab [odds ratio (OR) = 1.032, confidence interval (CI) = 1.007–1.057; P = 0.009], 2) duration of rituximab therapy [OR = 0.962, CI = 0.932–0.994; P = 0.021] and 3) G‐CSF administration [OR = 4.825, CI = 1.411–16.495; P = 0.012].Conclusions: Rituximab therapy may be associated with infection, indicating the need for sequential monitoring of IgM levels and identification of the optimal interval between rituximab cycles.Keywords
This publication has 21 references indexed in Scilit:
- Monoclonal Antibodies in the Treatment of Non-Hodgkin???s LymphomaDrugs, 2007
- Rituximab-related viral infections in lymphoma patientsLeukemia & Lymphoma, 2007
- High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complicationAnnals of Oncology, 2006
- Antibiotic prophylaxis in chemotherapy‐induced neutropenia: time to reconsiderHematological Oncology, 2006
- Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non‐Hodgkin lymphomaEuropean Journal of Haematology, 2006
- Tolerability and safety of rituximab (MabThera®)Cancer Treatment Reviews, 2005
- Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 scheduleBlood, 2004
- Rituximab: Expanding Role in Therapy for Lymphomas and Autoimmune DiseasesAnnual Review of Medicine, 2004
- Prolonged hypogammaglobulinemia following rituximab treatment for post transplant Epstein–Barr virus-associated lymphoproliferative diseaseBone Marrow Transplantation, 2003
- TREATMENT OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE WITH RITUXIMABTransplantation, 2002